260 related articles for article (PubMed ID: 31294337)
1. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.
Yu JK; Iorio A; Edginton AN;
Res Pract Thromb Haemost; 2019 Jul; 3(3):528-541. PubMed ID: 31294337
[TBL] [Abstract][Full Text] [Related]
2. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Stobart K; Iorio A; Wu JK
Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
[TBL] [Abstract][Full Text] [Related]
3. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Stobart K; Iorio A; Wu JK
Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
[TBL] [Abstract][Full Text] [Related]
4. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
Yu JK; Iorio A; Edginton AN
Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
[TBL] [Abstract][Full Text] [Related]
5. Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.
Preijers T; Schütte LM; Kruip MJHA; Cnossen MH; Leebeek FWG; van Hest RM; Mathôt RAA
Ther Drug Monit; 2019 Apr; 41(2):192-212. PubMed ID: 30883513
[TBL] [Abstract][Full Text] [Related]
6. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
7. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.
Iorio A; Edginton AN; Blanchette V; Blatny J; Boban A; Cnossen M; Collins P; Croteau SE; Fischer K; Hart DP; Ito S; Korth-Bradley J; Lethagen S; Lillicrap D; Makris M; Mathôt R; Morfini M; Neufeld EJ; Spears J
Res Pract Thromb Haemost; 2018 Jul; 2(3):535-548. PubMed ID: 30046759
[TBL] [Abstract][Full Text] [Related]
8. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.
Iorio A; Keepanasseril A; Foster G; Navarro-Ruan T; McEneny-King A; Edginton AN; Thabane L;
JMIR Res Protoc; 2016 Dec; 5(4):e239. PubMed ID: 27977390
[TBL] [Abstract][Full Text] [Related]
9. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.
Morfini M; Gherardini S
Ther Adv Hematol; 2018 Jun; 9(6):149-162. PubMed ID: 29899890
[TBL] [Abstract][Full Text] [Related]
11. Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).
McEneny-King A; Foster G; Iorio A; Edginton AN
JMIR Res Protoc; 2016 Dec; 5(4):e232. PubMed ID: 27927609
[TBL] [Abstract][Full Text] [Related]
12. Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products.
Teitel J; Sholzberg M; Iorio A
Res Pract Thromb Haemost; 2021 Feb; 5(2):349-355. PubMed ID: 33733034
[TBL] [Abstract][Full Text] [Related]
13. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence.
Ghosh K; Ghosh K
Expert Rev Hematol; 2021 Aug; 14(8):721-730. PubMed ID: 34278926
[TBL] [Abstract][Full Text] [Related]
14. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
15. Clotting factor concentrate switching and inhibitor development in hemophilia A.
Iorio A; Puccetti P; Makris M
Blood; 2012 Jul; 120(4):720-7. PubMed ID: 22692511
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.
Preijers T; Schütte LM; Kruip MJHA; Cnossen MH; Leebeek FWG; van Hest RM; Mathôt RAA
Clin Pharmacokinet; 2021 Jan; 60(1):1-16. PubMed ID: 32936401
[TBL] [Abstract][Full Text] [Related]
17. Importance of pharmacokinetics in the management of hemophilia.
Barnes C
Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
[TBL] [Abstract][Full Text] [Related]
18. Safety of Switching Factor VIII Products in the Era of Evolving Concentrates: Myths and Facts.
Coppola A; Marrone E; Conca P; Cimino E; Mormile R; Baldacci E; Santoro C
Semin Thromb Hemost; 2016 Jul; 42(5):563-76. PubMed ID: 27257871
[TBL] [Abstract][Full Text] [Related]
19. Using pharmacokinetics to individualize hemophilia therapy.
Iorio A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):595-604. PubMed ID: 29222309
[TBL] [Abstract][Full Text] [Related]
20. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.
McEneny-King A; Iorio A; Foster G; Edginton AN
Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1313-1321. PubMed ID: 27539370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
